TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 367511

Group type: EXPERIMENTAL
Intervention: naftidrofuryl
Number of subjects: 91

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 91
Study: 29448072

Group type: EXPERIMENTAL
Intervention: SB3
Number of subjects: 875

Group type: COMPARATOR
Intervention: TRZ
Number of subjects: 875
Study: 27223689

Group type: EXPERIMENTAL
Intervention: Music intervention (listening to preferred music for 30-45 minutes per night for 3 months)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (received sleep hygiene education and biweekly telephone calls)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study: 25536517

Group type: EXPERIMENTAL
Intervention: Task‐oriented visual feedback balance training
Number of subjects: 39
Study: 24167769

Group type: EXPERIMENTAL
Intervention: Urethral calibration
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 20695208

Group type: EXPERIMENTAL
Intervention: Cycloferon (injections and tablets)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remaxol (metabolic hepatoprotector with antioxidant activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triple therapy with immunomodulators (including cycloferon, galavit, and derinat)
Number of subjects: 0
Study: 18156372

Group type: EXPERIMENTAL
Intervention: Free spectacles (arm A)
Number of subjects: 6904

Group type: COMPARATOR
Intervention: Prescription only (arm B)
Number of subjects: 6904
Study: 16785215

Group type: EXPERIMENTAL
Intervention: Symptom-triggered (ST) dosing of lorazepam based on CIWA-Ar score
Number of subjects: 183

Group type: COMPARATOR
Intervention: Fixed-schedule (FS) dosing of lorazepam with tapering over 4 days
Number of subjects: 183
Study: 14605453

Group type: EXPERIMENTAL
Intervention: Unconventional anti-cancer drugs
Number of subjects: 30000
Study: 10830255

Group type: EXPERIMENTAL
Intervention: Systemic corticosteroids administered within the first 2 weeks of life
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diuretics and inhaled bronchodilators
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home oxygen therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis against respiratory syncytial virus
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant human superoxide dismutase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alpha-1 proteinase inhibitor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous surfactant
Number of subjects: 0
Study: 8633942

Group type: EXPERIMENTAL
Intervention: Heparin-coated circuit
Number of subjects: 102

Group type: COMPARATOR
Intervention: Uncoated circuit
Number of subjects: 102
Study: 1727807

Group type: EXPERIMENTAL
Intervention: 300 mg MEL administered daily (days 1-30) for 4 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: 300 mg MEL (days 5-17) and 75 mg MEL combined with 0.3 mg NET
Number of subjects: 32
Study: 6371876

Group type: EXPERIMENTAL
Intervention: Trazodone 50-200 mg once daily for 5 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Doxepin 25-100 mg once daily for 5 weeks
Number of subjects: 40
Study: 29577843

Group type: EXPERIMENTAL
Intervention: Moms' Empowerment Program (MEP), a 10-week group intervention
Number of subjects: 72

Group type: COMPARATOR
Intervention: Wait-list comparison condition
Number of subjects: 72
Study: 28971855

Group type: EXPERIMENTAL
Intervention: CIPP as a pretraining warm-up
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CIPP as a post-training cool-down
Number of subjects: 408

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: CIPP warm-up vs CIPP cool-down
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Adherence to the intervention
Number of subjects: 408
Study: 30024240

Group type: EXPERIMENTAL
Intervention: Self-evaluation of showing vulnerability
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Other-evaluation of showing vulnerability
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Level of construal
Number of subjects: 7
Study: 26791822

Group type: EXPERIMENTAL
Intervention: Group of 4 late-adolescent males (ages 18-22)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Group of 3 late-adolescent males with 1 slightly older adult (age 25-30)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Adolescents tested alone
Number of subjects: 4
Study: 24676877

Group type: EXPERIMENTAL
Intervention: Tasisulam sodium (targeting an albumin‐corrected exposure of 1200‐6400 h.μg/mL on day 1)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m² on days 1, 8, and 15 every 28 days)
Number of subjects: 336
Study: 22409642

Group type: EXPERIMENTAL
Intervention: Anglicized Battlemind intervention
Number of subjects: 2443

Group type: COMPARATOR
Intervention: U.K. standard postdeployment brief
Number of subjects: 2443
Study: 20178538

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted cervical cancer vaccine
Number of subjects: 354

Group type: COMPARATOR
Intervention: Aluminum hydroxide placebo
Number of subjects: 354
Study: 18622257

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 9624

Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 9624
Study: 16101180

Group type: EXPERIMENTAL
Intervention: Docetaxel 60 mg/m2 i.v. followed by irinotecan 200 mg/m2 i.v. on day 1 with rhG-CSF support from days 2 to 6, every 3 weeks
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Docetaxel plus irinotecan with rhG-CSF support
Number of subjects: 31
Study: 11834957

Group type: EXPERIMENTAL
Intervention: Surgical Treatment (ST)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cidofovir Treatment (CT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Surgical-Cidofovir Treatment (SCT)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Human Papillomavirus DNA Clearance
Number of subjects: 74
Study: 9893183

Group type: EXPERIMENTAL
Intervention: Low-sulfite red and white wines
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-sulfite white wine
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo wines
Number of subjects: 16
Study: 7717184

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: PETN (150 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (Healthy Controls)
Number of subjects: 20
Study: 2149509

Group type: EXPERIMENTAL
Intervention: Buserelin (nasal spray, 3 daily doses of 400 micrograms) combined with cyproterone acetate (CPA, 3 daily doses of 50 mg orally for 2 weeks)
Number of subjects: 367

Group type: COMPARATOR
Intervention: Orchidectomy (standard androgen-deprivative therapy)
Number of subjects: 367
Study: 6775537

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (4%)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 31685797

Group type: EXPERIMENTAL
Intervention: Chitosan oligosaccharide (GO2KA1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28457876

Group type: EXPERIMENTAL
Intervention: Simulated patient (SP) training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Live patient (LP) training
Number of subjects: 29
Study: 25479571

Group type: EXPERIMENTAL
Intervention: 0.8 g protein per kg body weight per day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 1.6 g protein per kg body weight per day
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: 2.4 g protein per kg body weight per day
Number of subjects: 39
Study: 22762536

Group type: EXPERIMENTAL
Intervention: PVC catheter
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: PVC-free LoFric catheter
Number of subjects: 104
Study: 21854282

Group type: EXPERIMENTAL
Intervention: OROS-methylphenidate (OROS-MPH)
Number of subjects: 255

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 255
Study: 19347752

Group type: EXPERIMENTAL
Intervention: Social Norms Marketing (SNM) campaigns
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group institutions (no SNM campaign)
Number of subjects: 0
Study: 16901714

Group type: EXPERIMENTAL
Intervention: Warm modified Calafiore cardioplegia (WARM group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cold blood cardioplegia (COLD group)
Number of subjects: 30
Study: 15113716

Group type: EXPERIMENTAL
Intervention: Nutritional intervention (feeding malnourished patients) for 1 month
Number of subjects: 15
Study: 11795364

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0
Study: 9555667

Group type: EXPERIMENTAL
Intervention: Exogenous norepinephrine (NE) at pressor doses (delta MAP = 20 mmHg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7995145

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (20 Gy total, divided into four daily fractions of 5 Gy each)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Surgical treatment alone
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy
Number of subjects: 284
Study: 2908216

Group type: COMPARATOR
Intervention: Chlordesmethyldiazepam 0.1 mg/kg i.v. (group C)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sodium thiopental 5 mg/kg i.v. (group T)
Number of subjects: 16
Study: 30760241

Group type: EXPERIMENTAL
Intervention: 300 mg CBD
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 29790420

Group type: EXPERIMENTAL
Intervention: Olfactory Training (OT)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (nOT)
Number of subjects: 42
Study: 25848127

Group type: EXPERIMENTAL
Intervention: Acupressure at the true point
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (sham) acupressure
Number of subjects: 60
Study: 24646366

Group type: COMPARATOR
Intervention: Daily interval training until a 25% decrement in time-to-fatigue performance (Study 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-intensity interval training (Study 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TDS scores obtained over a 2-week period before swimming competitions (Study 3)
Number of subjects: 0
Study: 22505376

Group type: EXPERIMENTAL
Intervention: Topical isosorbide dinitrate 10%
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Topical isosorbide dinitrate 5%
Number of subjects: 75

Group type: COMPARATOR
Intervention: Symptomatic treatments (control group)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Responsive patients (5 years later)
Number of subjects: 75
Study: 20200547

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) ± Hydrochlorothiazide (HCTZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine (AML) + Olmesartan Medoxomil (OM) + Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study: 17613297

Group type: EXPERIMENTAL
Intervention: Intravenous ghrelin (5 pmol/kg/min) infusion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 16
Study: 16040670

Group type: EXPERIMENTAL
Intervention: Intervention based on goal attainment scaling
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 11122834

Group type: EXPERIMENTAL
Intervention: Non-myeloablative preparative regimens
Number of subjects: 116
Study: 9054905

Group type: EXPERIMENTAL
Intervention: Psychiatrist/primary care model
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychiatrist/psychologist team model
Number of subjects: 0
Study: 8335833

Group type: EXPERIMENTAL
Intervention: Captopril (sulfhydryl‐containing angiotensin‐converting enzyme inhibitor)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intracoronary nitroglycerin (1‐ to 20‐micrograms doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2445091

Group type: EXPERIMENTAL
Intervention: YM-12617 (0.2 mg)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: YM-12617 (0.4 mg)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study: 2967855

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.3 micrograms/kg per min)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide infusion (0.1 microgram/kg per min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31517396

Group type: EXPERIMENTAL
Intervention: Serum analytes at 6 and 14 days post-injury
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Chitinase‐3‐like protein 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor binding protein 1
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Insulin‐like growth factor binding protein 5
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Renin
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Lymphotoxin alpha 1: beta 2
Number of subjects: 16
Study: 30058345

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 28319755

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study: 26051546

Group type: EXPERIMENTAL
Intervention: Conventional method (custom tray with impression compound and silicone)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Simplified method (stock tray and alginate)
Number of subjects: 24
Study: 23620504

Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 63
Study: 20171049

Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 215

Group type: COMPARATOR
Intervention: Uncemented acetabular components
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Bilateral cases
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Unilateral hip arthropathy
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Contralateral hip impairment, knee or spine problems, or significant comorbidities
Number of subjects: 215
Study: 16988203

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg (2 x 250 microg) after a high-fat meal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Roflumilast 500 microg (2 x 250 microg) after overnight fasting
Number of subjects: 12
Study: 14734879

Group type: EXPERIMENTAL
Intervention: Experimental formula (reduced total protein concentration enriched in bovine alpha-lactalbumin)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Experimental formula
Number of subjects: 193
Study: 11587609

Group type: EXPERIMENTAL
Intervention: Mitomycin (0.4 mg/mL, 2 mL solution applied for 2 minutes)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo, equal volume applied for 2 minutes)
Number of subjects: 24
Study: 9156373

Group type: EXPERIMENTAL
Intervention: sirolimus (0.5‐6.5 mg/m2/12 hr)
Number of subjects: 40
Study: 8181025

Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3331375

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and Tamoxifen (TAM)
Number of subjects: 66
Study: 31588902

Group type: EXPERIMENTAL
Intervention: RiksmatenFlexDiet
Number of subjects: 78

Group type: COMPARATOR
Intervention: Recall interviews
Number of subjects: 78
Study: 28259853

Group type: EXPERIMENTAL
Intervention: Early initiation of a cough management algorithm
Number of subjects: 214

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study: 26321102

Group type: EXPERIMENTAL
Intervention: Step-wise model of diabetes prevention
Number of subjects: 602

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 602
Study: 23370582

Group type: EXPERIMENTAL
Intervention: Water-based exercise (at least twice-weekly for 8 weeks)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (no water-based exercise)
Number of subjects: 29
Study: 21223307

Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Impulsivity (IMP)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity (AS) and anxiety
Number of subjects: 393
Study: 18445608

Group type: EXPERIMENTAL
Intervention: Flexed lateral position
Number of subjects: 82

Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 82
Study: 17132552

Group type: EXPERIMENTAL
Intervention: Intensive post-acute neuropsychological rehabilitation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-rehabilitated)
Number of subjects: 50
Study: 14767412

Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study: 10689260

Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9406

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 9406

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 9406

Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 9406
Study: 9337826

Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms b.i.d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluticasone 100 micrograms b.i.d
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Fluticasone 200 micrograms b.i.d
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 8408733

Group type: EXPERIMENTAL
Intervention: Quinidine sulfate (200 mg orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine-quinidine combination
Number of subjects: 10
Study: 3760461

Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for 5 days)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 10
Study: 31912198

Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with islet autoimmunity (18 months prior to first seroconversion)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with type 1 diabetes (18 months prior to first seroconversion)
Number of subjects: 732

Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with type 1 diabetes (at calendar age of 12 months)
Number of subjects: 732
Study: 30333336

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (3 g in 100 ml saline solution)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline solution (placebo, 100 ml)
Number of subjects: 70
Study: 26592763

Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study: 24892729

Group type: EXPERIMENTAL
Intervention: Toupet procedure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dor procedure
Number of subjects: 42
Study: 22349673

Group type: EXPERIMENTAL
Intervention: Ketamine-propofol-dexmedetomidine combination (KPD group, n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ketamine-propofol combination (KP group, n = 30)
Number of subjects: 60
Study: 20170424

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 203

Group type: COMPARATOR
Intervention: Intramedullary fixation
Number of subjects: 203
Study: 17509069

Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Metformin (titrated to 2000 mg daily)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 780

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 780
Study: 15708043

Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group (150 controls, 90 men and 60 women)
Number of subjects: 132
Study: 12424384

Group type: EXPERIMENTAL
Intervention: Moderate doses of alcohol
Number of subjects: 0
Study: 9523805

Group type: COMPARATOR
Intervention: 2.5 ml 2% lidocaine in 7.5% glucose
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2% prilocaine in 7.5% glucose
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine in 7.5% glucose
Number of subjects: 90
Study: 7915501

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 159
Study: 2672786

Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg per dose, administered at 8 AM and 12 PM on school days)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study: 1103209

Group type: EXPERIMENTAL
Intervention: marihuana containing 20 mg Delta‐9‐tetrahydrocannabinol
Number of subjects: 72

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study: 31504596

Group type: EXPERIMENTAL
Intervention: Testosterone gel for 12 months
Number of subjects: 790

Group type: COMPARATOR
Intervention: Placebo gel for 12 months
Number of subjects: 790
Study: 26897544

Group type: EXPERIMENTAL
Intervention: Vocal group therapy intervention
Number of subjects: 26
Study: 27562434

Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 13
Study: 25241220

Group type: EXPERIMENTAL
Intervention: ILR strategy (n = 39)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional evaluation strategy (CONV group, n = 39)
Number of subjects: 78
Study: 23040521

Group type: EXPERIMENTAL
Intervention: High-dose arginine (500 mg · kg(‐1) · d(‐1))
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low-dose arginine (100 mg · kg(‐1) · d(‐1)) combined with sodium phenylbutyrate (500 mg · kg(‐1) · d(‐1))
Number of subjects: 12
Study: 20500044

Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 354

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Higher potency statins
Number of subjects: 354

Group type: COMPARATOR
Intervention: Lower potency statins
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Rechallenge
Number of subjects: 354